Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.
VXRT stock had a great run today due to positive news from their norovirus vaccine. Shs Float is at 3.96M and their market cap is 16.12M. We will be watching this for a continuation play tomorrow. Watch my full video review for $VXRT by using the link in my signature description!
Yesterday positive results from phase 2 study of their oral vaccine against flu was released.
Seeking alpha: The vaccine elicited a significant expansion of mucosal homing receptor alfa4beta7+ (beta7+) plasmablasts, cells that play a key role in an immune response, to about 60% of all activated B cells, significantly higher than 20% from Sanofi's (NYSE:SNY)...
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.
VXRT
